First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP
Clinical trial NCT06460064 · COMPLETED
Trial details
- NCT number
- NCT06460064
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-26
- Primary completion
- 2026-03-31
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.